Advanced in Beta-Ketothiolase Deficiency

Karl O. Schwab

Mathilden Str. 1, 
Freiburg, BW, DE 
Advanced in Beta-Ketothiolase Deficiency
Mathilden Str. 1, 
Freiburg, BW, DE 
OverviewLocationsClinical Research

Overview

Karl Schwab practices in Freiburg, Germany. Mr. Schwab is rated as an Advanced expert by MediFind in the treatment of Beta-Ketothiolase Deficiency. His top areas of expertise are Small for Gestational Age, Pediatric Growth Hormone Deficiency, Growth Hormone Deficiency (GHD), and Type 1 Diabetes (T1D).

His clinical research consists of co-authoring 71 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Beta-Ketothiolase Deficiency.

Gender
Male

Locations

Mathilden Str. 1, Freiburg, BW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Heterozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol (ORION-16)
Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Heterozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol (ORION-16)
Enrollment Status: Completed
Publish Date: June 10, 2025
Intervention Type: Drug
Study Drug: Inclisiran
Study Phase: Phase 3
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: January 24, 2022
Intervention Type: Drug
Study Drugs: LY900014, Insulin Lispro
Study Phase: Phase 3
View 1 Less Clinical Trial

71 Total Publications

Gestational diabetes mellitus: the role of IGF-1 and leptin in cord blood.
Gestational diabetes mellitus: the role of IGF-1 and leptin in cord blood.
Journal: Journal of perinatal medicine
Published: April 17, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schwab's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 27 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile